Abortion-inducing drugs; Protecting Moms and Babies Act; terms; exclusions; manufacture or distribute; mail, transport, deliver, prescribe, or provide; exception; qui tam actions; enforcement of prohibitions; defenses; statute of limitation; remedies; personal jurisdiction and applicability of state law; jurisdiction of appeals; protections from counteractions; severability clause; effective date.
HB2945, titled the "Protecting Moms and Babies Act," would create a new state law aimed at abortion-inducing drugs. It defines "abortion" and "abortion-inducing drug" broadly, specifically naming drugs such as mifepristone (Mifeprex), misoprostol (Cytotec), and methotrexate when used with the intent to terminate a pregnancy. The bill generally prohibits manufacturing, distributing, mailing, transporting, delivering, prescribing, furnishing, or providing abortion-inducing drugs in Oklahoma, while carving out exceptions for life-saving treatment for the mother, ectopic pregnancies, miscarriage management, and other non-abortion medical uses.
The bill also establishes a private-enforcement model through qui tam actions. Under the proposal, the state and its political subdivisions would be barred from directly enforcing the prohibition, and instead private individuals could sue alleged violators as assignees of the state’s claim. The bill sets a six-year limitations period, provides for injunctive relief, at least $100,000 per violation, and attorney fees for successful relators, and includes detailed rules on standing, defenses, venue, jurisdiction, and limits on class actions. It also attempts to block the application of other states’ laws, restrict counter-suits or "clawback" actions, and protect relators and related parties from certain out-of-state legal retaliation.
If enacted, HB2945 would significantly alter Oklahoma law by adding a new chapter-like set of provisions in Title 63 governing abortion-inducing drugs and civil enforcement. It would affect pharmacies, physicians, health care professionals, distributors, manufacturers, common carriers, and others involved in the supply chain, while expressly exempting the pregnant woman herself from suit. The bill also seeks to extend Oklahoma courts’ personal jurisdiction and make Oklahoma law controlling in these cases, even when conduct or litigation has multistate connections.
The general sentiment reflected in the available voting history is unfavorable in committee: the House Civil Judiciary Committee voted 3-5 against a motion to do pass as amended by committee substitute. No transcript excerpts are available, so the record does not show detailed debate, but the vote suggests substantial resistance. Given the bill’s sweeping restrictions, private-enforcement mechanism, and aggressive jurisdictional provisions, likely points of contention include its impact on reproductive health access, its use of qui tam litigation, and its attempt to limit defenses and out-of-state legal protections.
HB2945 would add new statutory provisions to Title 63 of the Oklahoma Statutes creating a broad civil prohibition on abortion-inducing drugs and a private right of action to enforce it. It would regulate conduct by manufacturers, distributors, prescribers, providers, and transporters, while exempting certain medical exceptions and the pregnant woman herself. The bill also attempts to preempt or neutralize contrary out-of-state laws and shield laws, expand Oklahoma courts’ jurisdiction, and impose special rules for appeals, defenses, and remedies.
The available voting history indicates the bill faced opposition in committee, with the House Civil Judiciary Committee rejecting a do-pass motion by a 3-5 vote. Because no committee transcript is available, there is no direct record of floor-style debate, but the vote suggests the proposal was controversial and did not have broad support at that stage. The bill’s strong anti-abortion posture and unusual private-enforcement structure likely contributed to the negative reaction.
The main points of contention are likely the bill’s near-total prohibition on abortion-inducing drugs, its reliance on qui tam enforcement by private relators rather than state officials, and its attempt to foreclose defenses based on constitutional claims, other states’ laws, or certain preclusion doctrines. Opponents would likely focus on reproductive rights, access to medication abortion, and the bill’s reach into interstate commerce and health care practice, while supporters would emphasize fetal protection, enforcement through private lawsuits, and the stated medical exceptions. The bill also appears designed to provoke legal scrutiny over jurisdiction, extraterritorial application, and conflict with federal law.